BRPI0818804A2 - Composto derivado de pirimidina, composição farmacêutica que o compreende e uso desse composto. - Google Patents

Composto derivado de pirimidina, composição farmacêutica que o compreende e uso desse composto.

Info

Publication number: BRPI0818804A2
Authority: BR; Brazil
Prior art keywords: compound; pharmaceutical composition; pyrimidine derivative; derivative compound; pyrimidine
Prior art date: 2007-11-01

Application number

Other languages

English (en)

Inventor

Martin Bolli

Claus Mueller

Boris Mathys

Olivier Nayler

Beat Steiner

Cyrille Lescop

Original Assignee

Actelion Pharmaceuticals Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-11-01

Filing date

2008-10-31

Publication date

2015-04-22

2008-10-31 Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd

2015-04-22 Publication of BRPI0818804A2 publication Critical patent/BRPI0818804A2/pt

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Diabetes (AREA)
Pulmonology (AREA)
Ophthalmology & Optometry (AREA)
Endocrinology (AREA)
Dermatology (AREA)
Rheumatology (AREA)
Neurosurgery (AREA)
Hematology (AREA)
Obesity (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Transplantation (AREA)
Pain & Pain Management (AREA)
Oncology (AREA)
Emergency Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Urology & Nephrology (AREA)
Otolaryngology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

BRPI0818804 2007-11-01 2008-10-31 Composto derivado de pirimidina, composição farmacêutica que o compreende e uso desse composto. BRPI0818804A2 (pt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
IB2007054437		2007-11-01
PCT/IB2008/054543 WO2009057079A2 (en)	2007-11-01	2008-10-31	Novel pyrimidine derivatives

Publications (1)

Publication Number	Publication Date
BRPI0818804A2 true BRPI0818804A2 (pt)	2015-04-22

Family

ID=40577704

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0818804 BRPI0818804A2 (pt)	2007-11-01	2008-10-31	Composto derivado de pirimidina, composição farmacêutica que o compreende e uso desse composto.

Country Status (18)

Country	Link
US (1)	US8299086B2 (pt)
EP (1)	EP2217594B1 (pt)
JP (1)	JP5517944B2 (pt)
KR (1)	KR20100092473A (pt)
CN (1)	CN101970430B (pt)
AR (1)	AR069146A1 (pt)
AU (1)	AU2008320374A1 (pt)
BR (1)	BRPI0818804A2 (pt)
CA (1)	CA2700917A1 (pt)
ES (1)	ES2449749T3 (pt)
IL (1)	IL205425A0 (pt)
MA (1)	MA31849B1 (pt)
MX (1)	MX2010004576A (pt)
NZ (1)	NZ585775A (pt)
RU (1)	RU2010121969A (pt)
TW (1)	TW200920746A (pt)
WO (1)	WO2009057079A2 (pt)
ZA (1)	ZA201003875B (pt)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PT2069336E (pt) *	2006-09-07	2013-03-07	Actelion Pharmaceuticals Ltd	Derivados de piridin-4-ilo como agentes imunomoduladores
PL2069335T3 (pl)	2006-09-08	2013-05-31	Actelion Pharmaceuticals Ltd	Pochodne pirydyn-3-ylu jako środki immunomodulujące
CA2663254C (en)	2006-09-15	2016-04-19	Reviva Pharmaceuticals, Inc.	Synthesis, methods of using, and compositions of cycloalkylmethylamines
ES2393412T3 (es) *	2006-09-21	2012-12-21	Actelion Pharmaceuticals Ltd.	Derivados de fenilo y su uso como inmunomoduladores
BRPI0808789A2 (pt) *	2007-03-16	2014-08-12	Actelion Pharmaceuticals Ltd	Compostos e composição farmacêutica de derivados aminopiridina e uso destes
PT2195311E (pt) *	2007-08-17	2011-05-25	Actelion Pharmaceuticals Ltd	Derivados de piridina como moduladores do receptor s1p1/edg1
EP2262799B1 (en) *	2008-03-06	2012-07-04	Actelion Pharmaceuticals Ltd.	Pyridine compounds
WO2009109907A1 (en) *	2008-03-06	2009-09-11	Actelion Pharmaceuticals Ltd	Novel pyrimidine-pyridine derivatives
WO2009109872A1 (en) *	2008-03-07	2009-09-11	Actelion Pharmaceuticals Ltd	Pyridin-2-yl derivatives as immunomodulating agents
CA2715317A1 (en) *	2008-03-07	2009-09-11	Actelion Pharmaceuticals Ltd	Novel aminomethyl benzene derivatives
WO2010085582A1 (en)	2009-01-23	2010-07-29	Bristol-Myers Squibb Company	Substituted oxadiazole derivatives as s1p agonists in the treatment of autoimmune and inflammatory diseases
JP2012515787A (ja)	2009-01-23	2012-07-12	ブリストル−マイヤーズスクイブカンパニー	自己免疫疾患および炎症性疾患の処置におけるｓ１ｐアゴニストとしての置換オキサジアゾール誘導体
ES2405054T3 (es)	2009-01-23	2013-05-30	Bristol-Myers Squibb Company	Derivados de pirazol-1,2,4-oxadiazol como agonistas de esfingosina-1-fosfato
CA2767585C (en)	2009-07-16	2017-09-26	Actelion Pharmaceuticals Ltd	Pyridin-4-yl derivatives
US8399451B2 (en) *	2009-08-07	2013-03-19	Bristol-Myers Squibb Company	Heterocyclic compounds
US9216972B2 (en)	2009-10-29	2015-12-22	Bristol-Myers Squibb Company	Tricyclic heterocyclic compounds
ES2548683T3 (es)	2010-04-23	2015-10-20	Bristol-Myers Squibb Company	Amidas del ácido 4-(5-isoxazolil o 5-pirrazolil-1,2,4-oxadiazol-3-il)-mandélico como agonistas de receptor de esfingosina-1-fosfato 1
WO2012003501A2 (en)	2010-07-02	2012-01-05	Reviva Pharmaceuticals, Inc.	Compositions, synthesis, and methods of using cycloalkylmethylamine derivatives
US8822510B2 (en)	2010-07-20	2014-09-02	Bristol-Myers Squibb Company	Substituted 3-phenyl-1,2,4-Oxadiazole compounds
EP2619190B1 (en)	2010-09-24	2015-08-12	Bristol-Myers Squibb Company	Substituted oxadiazole compounds and their use as s1p1 agonists
EP2635573B1 (en)	2010-11-03	2014-10-01	Bristol-Myers Squibb Company	Heterocyclic compounds as s1p1 agonists for the treatment of autoimmune and vascular diseases
MA34910B1 (fr)	2011-01-19	2014-02-01	Actelion Pharmaceuticals Ltd	Dérivés de 2-methoxy-pyridin-4-yl
US9238625B2 (en) *	2011-12-30	2016-01-19	Reviva Pharmaceuticals, Inc.	Compositions, synthesis, and methods of using phenylcycloalkylmethylamine derivatives
US9115054B2 (en)	2013-02-21	2015-08-25	Bristol-Myers Squibb Company	Tetrahydronaphthalenyl compounds useful as sipi agonists
NZ713080A (en)	2013-03-15	2020-06-26	Idorsia Pharmaceuticals Ltd	Pyridin-4-yl derivatives
MA40082B1 (fr)	2014-08-20	2019-09-30	Bristol Myers Squibb Co	Nouveau compose de substitution sphingosine phosphate utile traitement maladie rhumatisme
PH12017502097B1 (en)	2015-05-20	2023-05-05	Idorsia Pharmaceuticals Ltd	Crystalline form of the compound (s)-3-{4-[5-(2-cyclopentyl-6-methoxy-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-propane-1,2-diol
WO2017004609A1 (en) *	2015-07-02	2017-01-05	Exelixis, Inc.	Thiadiazole modulators of s1p and methods of making and using
KR102482825B1 (ko)	2016-09-02	2022-12-29	브리스톨-마이어스 스큅 컴퍼니	치환된 트리시클릭 헤테로시클릭 화합물
US11059784B2 (en)	2017-08-09	2021-07-13	Bristol-Myers Squibb Company	Oxime ether compounds
US11046646B2 (en)	2017-08-09	2021-06-29	Bristol-Myers Squibb Company	Alkylphenyl compounds
WO2025230998A1 (en) *	2024-04-30	2025-11-06	University Of Massachusetts	Tec kinase agonists and their use in enhancing lymphocyte activation

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU7686891A (en)	1990-04-05	1991-10-30	American National Red Cross, The	A protein family related to immediate-early protein expressed by human endothelial cells during differentiation
US6423508B1 (en)	1998-03-09	2002-07-23	Smithkline Beecham Corporation	Polynucleotide sequences of human EDG-1c
KR100875222B1 (ko)	1999-08-19	2008-12-19	아스트라제네카 아베	헤테로폴리사이클릭 화합물 및 간접 글루타메이트 수용체길항제로서의 그들의 용도
US6559140B2 (en) *	2000-03-09	2003-05-06	Abbott Laboratories	Cyclic and bicyclic diamino histamine-3 receptor antagonists
ATE325608T1 (de) *	2001-08-13	2006-06-15	Janssen Pharmaceutica Nv	2,4,5-trisubstituted thiazolyl derivative und deren antiinflammatorische wirkung
ATE448193T1 (de)	2002-01-18	2009-11-15	Merck & Co Inc	ßN-(BENZYL)AMINOALKYL CARBOXYLATE, PHOSPHINATE, PHOSPHONATE UND TETRAZOLE ALS EDG REZEPTORAGONISTENß
JP4430941B2 (ja)	2002-01-18	2010-03-10	メルクエンドカムパニーインコーポレーテッド	Ｅｄｇ受容体作動薬
US7361665B2 (en) *	2002-07-09	2008-04-22	Vertex Pharmaceuticals Incorporated	Inhibitors of c-Jun N-terminal kinases (JNK) and other protein kinases
WO2004035538A1 (en)	2002-10-15	2004-04-29	Merck & Co., Inc.	Process for making azetidine-3-carboxylic acid
AU2004240586A1 (en) *	2003-05-15	2004-12-02	Merck & Co., Inc.	3-(2-amino-1-azacyclyl)-5-aryl-1,2,4-oxadiazoles as S1P receptor agonists
US20070043014A1 (en) *	2003-10-01	2007-02-22	Merck & Co., Inc.	3,5-Aryl, heteroaryl or cycloalkyl substituted-1,2,4-oxadiazoles as s1p receptor agonists
EP1697333A4 (en)	2003-12-17	2009-07-08	Merck & Co Inc	(3,4-DISUBSTITUTED) PROPANE ACID BOXYLATES AS AGONISTS OF THE S1P (EDG) RECEPTOR
EP1758579A1 (en)	2004-05-29	2007-03-07	7TM Pharma A/S	Crth2 receptor ligands for medicinal uses
CA2583681A1 (en)	2004-10-22	2006-05-04	Merck & Co., Inc.	2-(aryl)azacyclylmethyl carboxylates, sulfonates, phosphonates, phosphinates and heterocycles as s1p receptor agonists
EP1831207B1 (en) *	2004-12-17	2012-11-14	Amgen Inc.	Aminopyrimidine compounds as plk inhibitors
WO2006131336A1 (en)	2005-06-08	2006-12-14	Novartis Ag	POLYCYCLIC OXADIAZOLES OR I SOXAZOLES AND THEIR USE AS SlP RECEPTOR LIGANDS
CN101203220A (zh)	2005-06-28	2008-06-18	阿斯利康(瑞典)有限公司	新用途
TWI404706B (zh) *	2006-01-11	2013-08-11	Actelion Pharmaceuticals Ltd	新穎噻吩衍生物
GB0601744D0 (en)	2006-01-27	2006-03-08	Novartis Ag	Organic compounds
KR20080096780A (ko)	2006-02-21	2008-11-03	유니버시티 오브 버지니아 페이턴트 파운데이션	Ｓ１ｐ 수용체 효능제로서의 페닐-시클로알킬 및 페닐-헤테로시클릭 유도체
PT2069336E (pt) *	2006-09-07	2013-03-07	Actelion Pharmaceuticals Ltd	Derivados de piridin-4-ilo como agentes imunomoduladores
PL2069335T3 (pl) *	2006-09-08	2013-05-31	Actelion Pharmaceuticals Ltd	Pochodne pirydyn-3-ylu jako środki immunomodulujące
ES2393412T3 (es) *	2006-09-21	2012-12-21	Actelion Pharmaceuticals Ltd.	Derivados de fenilo y su uso como inmunomoduladores
EP2109364A4 (en)	2006-12-15	2010-04-14	Abbott Lab	NOVEL OXADIAZONE COMPOUNDS
WO2008091967A1 (en)	2007-01-26	2008-07-31	Smithkline Beecham Corporation	Chemical compounds
BRPI0808789A2 (pt) *	2007-03-16	2014-08-12	Actelion Pharmaceuticals Ltd	Compostos e composição farmacêutica de derivados aminopiridina e uso destes
EP2262799B1 (en) *	2008-03-06	2012-07-04	Actelion Pharmaceuticals Ltd.	Pyridine compounds
CA2715317A1 (en) *	2008-03-07	2009-09-11	Actelion Pharmaceuticals Ltd	Novel aminomethyl benzene derivatives
WO2009109872A1 (en) *	2008-03-07	2009-09-11	Actelion Pharmaceuticals Ltd	Pyridin-2-yl derivatives as immunomodulating agents
EP3782991A1 (en)	2008-05-14	2021-02-24	The Scripps Research Institute	Novel modulators of sphingosine phosphate receptors
CA2767585C (en) *	2009-07-16	2017-09-26	Actelion Pharmaceuticals Ltd	Pyridin-4-yl derivatives

2008
- 2008-10-31 KR KR1020107012070A patent/KR20100092473A/ko not_active Withdrawn
- 2008-10-31 RU RU2010121969/04A patent/RU2010121969A/ru not_active Application Discontinuation
- 2008-10-31 TW TW097142254A patent/TW200920746A/zh unknown
- 2008-10-31 JP JP2010531628A patent/JP5517944B2/ja not_active Expired - Fee Related
- 2008-10-31 BR BRPI0818804 patent/BRPI0818804A2/pt not_active IP Right Cessation
- 2008-10-31 AR ARP080104783A patent/AR069146A1/es not_active Application Discontinuation
- 2008-10-31 EP EP08846160.3A patent/EP2217594B1/en not_active Not-in-force
- 2008-10-31 ES ES08846160.3T patent/ES2449749T3/es active Active
- 2008-10-31 MX MX2010004576A patent/MX2010004576A/es not_active Application Discontinuation
- 2008-10-31 US US12/738,110 patent/US8299086B2/en not_active Expired - Fee Related
- 2008-10-31 WO PCT/IB2008/054543 patent/WO2009057079A2/en not_active Ceased
- 2008-10-31 CN CN2008801140168A patent/CN101970430B/zh not_active Expired - Fee Related
- 2008-10-31 NZ NZ585775A patent/NZ585775A/en not_active IP Right Cessation
- 2008-10-31 CA CA2700917A patent/CA2700917A1/en not_active Abandoned
- 2008-10-31 AU AU2008320374A patent/AU2008320374A1/en not_active Abandoned
2010
- 2010-04-29 IL IL205425A patent/IL205425A0/en unknown
- 2010-05-17 MA MA32838A patent/MA31849B1/fr unknown
- 2010-05-31 ZA ZA2010/03875A patent/ZA201003875B/en unknown

Also Published As

Publication number	Publication date
US20100234346A1 (en)	2010-09-16
RU2010121969A (ru)	2011-12-10
WO2009057079A2 (en)	2009-05-07
NZ585775A (en)	2011-12-22
MX2010004576A (es)	2010-05-17
CA2700917A1 (en)	2009-05-07
JP2011502980A (ja)	2011-01-27
WO2009057079A3 (en)	2009-12-03
AR069146A1 (es)	2009-12-30
CN101970430A (zh)	2011-02-09
EP2217594A2 (en)	2010-08-18
CN101970430B (zh)	2013-05-08
IL205425A0 (en)	2010-12-30
ES2449749T3 (es)	2014-03-21
TW200920746A (en)	2009-05-16
KR20100092473A (ko)	2010-08-20
US8299086B2 (en)	2012-10-30
MA31849B1 (fr)	2010-11-01
ZA201003875B (en)	2012-08-29
EP2217594B1 (en)	2014-01-08
AU2008320374A1 (en)	2009-05-07
JP5517944B2 (ja)	2014-06-11

Publication	Publication Date	Title
BRPI0818804A2 (pt)	2015-04-22	Composto derivado de pirimidina, composição farmacêutica que o compreende e uso desse composto.
BRPI0815190A2 (pt)	2015-03-31	Composto derivado de piridina, composição farmacêutica que o compreende e uso do mesmo
BRPI0814593A2 (pt)	2015-01-20	Composto, composição farmacêutica que o contém e uso do composto.
BRPI0815079A2 (pt)	2015-02-03	Composto dericado de 1,2-diamido-etileno, composição farmacêutica que contém e uso desse composto
BRPI0821004A2 (pt)	2015-06-16	Composto derivado de aminopirazol, composição farmacêutica que o contem e uso deste
BRPI0908208A2 (pt)	2015-08-25	Composto derivado de oxazolidinona, medicamento, composição farmacêutica que o contém e uso desse composto.
BRPI0716171A2 (pt)	2013-09-17	composto, composiÇço farmacÊutica e uso de um composto.
BRPI0815709A2 (pt)	2017-06-13	composro, composição farmacêutica, e, uso de um composto.
BRPI0614205A2 (pt)	2016-11-22	composto, composição farmacêutica, e, uso de composto
BRPI0815170A2 (pt)	2015-03-31	Composição farmacêutica que compreende um inibidor de sglt 2
BRPI0720124A2 (pt)	2014-03-04	Composições farmacêuticas e seus métodos de uso.
BRPI0618904A2 (pt)	2016-09-13	composto, composição farmacêutica, e, uso do composto
BRPI0810696A2 (pt)	2014-10-21	Composto, composição farmacêutica, e, uso de um composto
CL2007003226A1 (es)	2008-02-08	Compuestos derivados de piridinona; composicion farmaceutica; y uso para tratar el cancer.
BRPI0609802A2 (pt)	2017-05-02	composto, composição farmacêutica e uso de um composto
BRPI0809977A2 (pt)	2014-10-07	Uso de um composto, compostos e composição farmacêutica que o contém
CL2007002916A1 (es)	2008-04-18	Compuestos derivados de pirazoliltienopiridinas; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en la inhibicion de escaras.
SMP200900058B (it)	2010-11-12	Composti e composizioni come inibitori di proteinachinasi.
SM201000108A (it)	2011-01-19	Composti e composizioni come inibitori di proteinachinasi.
BRPI0821115A2 (pt)	2015-06-16	Composto derivado de aminotriazol, medicamento, composição farmacêutica e uso do composto
CL2007002377A1 (es)	2008-04-04	Compuestos derivados de quinazolina; procedimiento de preparacion; composicion farmaceutica; y su uso como anticancerigeno.
BRPI0813341A2 (pt)	2014-12-23	" uso de compostos, composições curáveis, e, uso de composições curáveis ".
CL2007001630A1 (es)	2008-02-08	Compuestos derivados de pirrolidinamida; composicion farmaceutica; y uso para el tratamiento de la hepatitis c.
BRPI0815360A2 (pt)	2015-02-10	Composto derivado de 4-pirimidinossulfamida, composição farmacêutica que o contem, uso e processo para pa preparação do composto
BRPI0917661A2 (pt)	2015-12-01	produto que contém macitentan, composição farmacêutica que o contém e uso de macitentan

Legal Events

Date	Code	Title	Description
2015-12-01	B08F	Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]	Free format text: REFERENTE AS 5A, 6A E 7A ANUIDADES.
2016-04-05	B08K	Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]	Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2343 DE 01-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.